Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial-Reference-Cited by-同舟云学术

Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial

Published:2021-06 Issue:6 Volume:22 Page:883-892
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Sacco Assuntina G,Chen Ruifeng,Worden Francis P,Wong Deborah J L,Adkins Douglas,Swiecicki Paul,Chai-Ho Wanxing,Oppelt Peter,Ghosh Debanjali,Bykowski Julie,Molinolo Alfredo,Pittman Emily,Estrada M Valeria,Gold Kathryn,Daniels Gregory,Lippman Scott M,Natsuhara Amanda,Messer Karen,Cohen Ezra E W

Funder

Merck Sharp & Dohme Ltd

Publisher

Elsevier BV

Subject

Oncology

Reference25 articles.

1. Current treatment options for recurrent or metastatic head and neck squamous cell carcinoma;Sacco;J Clin Oncol,2015

2. Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy

3. A randomized, phase 2 study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck;Seiwert;Ann Oncol,2014

4. Pembrolizumab versus methotrexate, docetaxel or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study;Cohen;Lancet,2019

5. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicenter, phase 1b trial;Seiwert;Lancet Oncol,2016

Cited by 154 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy in Head and Neck Cancer;Surgical Oncology Clinics of North America;2024-10

2. Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study;Nature Communications;2024-08-23

3. The Mutational and Microenvironmental Landscape of Cutaneous Squamous Cell Carcinoma: A Review;Cancers;2024-08-21

4. Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives;Signal Transduction and Targeted Therapy;2024-08-02

5. Less is more: Exploring neoadjuvant immunotherapy as a de-escalation strategy in head and neck squamous cell carcinoma treatment;Cancer Letters;2024-08